Study of belumosudil for cGVHD in diverse patients withdrawn
NCT ID NCT05567406
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to test the safety and effectiveness of the oral drug belumosudil in Black, Native American, and Pacific Islander patients aged 12 and older with chronic graft-versus-host disease (cGVHD) who had already tried at least two other treatments. The goal was to see if the drug could help control the disease without causing serious side effects. However, the study was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST-DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.